| Literature DB >> 21573090 |
Stefano Zenoni1, Mario R Romano, Sonia Palmieri, Natalia Comi, Edoardo Fiorentini, Piero Fontana.
Abstract
OBJECTIVE: The aim of the study was to evaluate the ocular tolerance and efficacy of double filling with perfluoro-n-octane (n-C8F18) (PFO) and polydimethyloxane (PDMS) as a temporary vitreous substitute in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).Entities:
Keywords: double filling; perfluoro-n-octane; polydimethyloxane; proliferative vitreo-retinopathy; retinal detachment; retinal detachment electrophysiology
Year: 2011 PMID: 21573090 PMCID: PMC3090297 DOI: 10.2147/OPTH.S17315
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Demographics data of patients
| G/A | 24 | M | 3,0 | 16 | Clear | Posterior break | x |
| S/M | 83 | M | 3,0 | 14 | Cortical opacities | Post-traumatic RD | |
| T/T | 30 | M | 2,0 | 4 | Pseudophakia | Posterior break | x |
| CM/D | 77 | F | 2,0 | 13 | Initial nuclear sclerosis | Post-traumatic RD | |
| G/B | 67 | F | 3,0 | 16 | Pseudophakia | Posterior break | |
| A/P | 50 | F | 1,0 | 17 | Nuclear sclerosis | Post-traumatic RD | |
| V/V | 57 | F | 2,0 | 14 | Nuclear sclerosis | Posterior break | x |
| F/T | 59 | M | 3,0 | 12 | Pseudophakia | ||
| T/F | 25 | F | 3,0 | 18 | Clear | Posterior break | x |
| E/G | 82 | M | 2,0 | 15 | Post-traumatic lens dislocation | Post-traumatic RD | |
| L/L | 72 | M | 3,0 | 14 | Clear | Post-traumatic RD | |
| G/M | 65 | M | 3,0 | 4 | Cortical opacities | ||
| A/B | 42 | M | 2,0 | 13 | Pseudophakia | Posterior break | x |
| G/C | 60 | M | 2,0 | 16 | Clear | ||
| G/P | 47 | M | 3,0 | 17 | Pseudophakia | Post-traumatic RD | |
| G/V | 43 | M | 3,0 | 18 | Nuclear sclerosis | Posterior break | x |
| S/P | 64 | M | 1,0 | 18 | Nuclear sclerosis | Post-traumatic RD | |
| D/B | 70 | M | 3,0 | 14 | Pseudophakia | Post-traumatic RD | |
| C/A | 41 | M | 3,0 | 12 | Clear | Posterior break | x |
| N/C | 37 | M | 3,0 | 10 | Initial nuclear sclerosis | Posterior break | x |
| B/T | 67 | F | 3,0 | 18 | Clear | Posterior break | |
| S/E | 49 | F | 2,0 | 10 | Clear | Post-traumatic RD | |
| G/P | 57 | F | 3,0 | 23 | Pseudophakia | Post-traumatic RD | |
| A/A | 50 | F | 3,0 | 17 | Clear | ||
| L/M | 70 | F | 1,0 | 17 | Nuclear sclerosis | Post-traumatic RD | |
| G/V | 37 | F | 2,0 | 16 | Nuclear sclerosis | Posterior break | x |
| N/S | 24 | F | 3,0 | 15 | Clear | x | |
| G/S | 83 | F | 3,0 | 16 | Pseudophakia | ||
| M/D | 55 | F | 3,0 | 18 | Clear | Post-traumatic RD | |
| F/F | 52 | F | 2,0 | 15 | Nuclear sclerosis | Posterior break |
Abbreviations: IOP, intraocular pressure; RD, retinal detachment.
Pre-double filling removal data
| G/A | 24 | M | 18 | Clear | 19 | x | x | ||
| S/M | 83 | M | 19 | Cortical opacities | 27 | x | x | ||
| T/T | 30 | M | 10 | Pseudophakia | 23 | ||||
| CM/D | 77 | F | 15 | Initial nuclear sclerosis | 24 | x | x | x | |
| G/B | 67 | F | 18 | Pseudophakia | 20 | ||||
| A/P | 50 | F | 27 | Nuclear sclerosis | 26 | x | x | x | |
| V/V | 57 | F | 20 | Nuclear sclerosis | 23 | x | x | ||
| F/T | 59 | M | 32 | Pseudophakia | 21 | ||||
| T/F | 25 | F | 40 | Clear | 25 | x | |||
| E/G | 82 | M | 17 | Post-traumatic lens dislocation | 26 | x | |||
| L/L | 72 | M | 29 | Clear | 23 | x | x | ||
| G/M | 65 | M | 11 | Cortical opacities | 23 | x | |||
| A/B | 42 | M | 25 | Pseudophakia | 21 | x | |||
| G/C | 60 | M | 25 | Clear | 26 | ||||
| G/P | 47 | M | 24 | Pseudophakia | 27 | x | x | ||
| G/V | 43 | M | 28 | Nuclear sclerosis | 23 | x | |||
| S/P | 64 | M | 24 | Nuclear sclerosis | 22 | x | x | x | |
| D/B | 70 | M | 14 | Pseudophakia | 25 | ||||
| C/A | 41 | M | 30 | Clear | 21 | x | x | ||
| N/C | 37 | M | 27 | Initial nuclear sclerosis | 23 | x | x | ||
| B/T | 67 | F | 18 | Clear | 27 | ||||
| S/E | 49 | F | 10 | Clear | 23 | ||||
| G/P | 57 | F | 32 | Pseudophakia | 24 | x | |||
| A/A | 50 | F | 17 | Clear | 22 | ||||
| L/M | 70 | F | 17 | Nuclear sclerosis | 23 | x | |||
| G/V | 37 | F | 16 | Nuclear sclerosis | 23 | x | |||
| N/S | 24 | F | 25 | Clear | 25 | x | |||
| G/S | 83 | F | 18 | Pseudophakia | 21 | ||||
| M/D | 55 | F | 15 | Clear | 20 | x | |||
| F/F | 52 | F | 30 | Nuclear sclerosis | 26 | x | x | ||
Abbreviations: IOP, intraocular pressure; PVR, proliferative vitreoretinopathy.
Postoperative data (3 months)
| G/A | 24 | M | 1,3 | 18 | |||
| S/M | 83 | M | 3,0 | 16 | |||
| T/T | 30 | M | 3,0 | 11 | x | ||
| CM/D | 77 | F | 3,0 | 27 | x | ||
| G/B | 67 | F | 2,0 | 19 | |||
| A/P | 50 | F | 1,0 | 18 | |||
| V/V | 57 | F | 1,3 | 20 | x | ||
| F/T | 59 | M | 3,0 | 16 | |||
| T/F | 25 | F | 1,0 | 32 | x | ||
| E/G | 82 | M | 2,0 | 18 | |||
| L/L | 72 | M | 3,0 | 16 | x | ||
| G/M | 65 | M | 3,0 | 11 | x | ||
| A/B | 42 | M | 3,0 | 27 | x | ||
| G/C | 60 | M | 0,7 | 18 | |||
| G/P | 47 | M | 2,0 | 19 | x | ||
| G/V | 43 | M | 1,0 | 18 | |||
| S/P | 64 | M | 1,0 | 20 | x | ||
| D/B | 70 | M | 3,0 | 16 | |||
| C/A | 41 | M | 1,0 | 32 | x | ||
| N/C | 37 | M | 2,0 | 18 | |||
| B/T | 67 | F | 3,0 | 16 | x | ||
| S/E | 49 | F | 3,0 | 27 | x | ||
| G/P | 57 | F | 0,7 | 18 | |||
| A/A | 50 | F | 2,0 | 19 | |||
| L/M | 70 | F | 1,0 | 18 | |||
| G/V | 37 | F | 1,0 | 20 | x | ||
| N/S | 24 | F | 1,3 | 16 | |||
| G/S | 83 | F | 3,0 | 16 | x | ||
| M/D | 55 | F | 1,0 | 32 | x | ||
| F/F | 52 | F | 2,0 | 18 | |||
Abbreviations: CME, cystoid macular edema; IOP, intraocular pressure; PVR, proliferative vitreoretinopathy.
Electroretinogram evaluation data at 2 weeks and 8 weeks after surgery
| G/A | 65,8 | 62,9 | −2,9 | G/A | 142,9 | 115,4 | −27,5 |
| S/M | 76,9 | 59,8 | −17,1 | S/M | 160,5 | 200,5 | 40 |
| L/M | 90,9 | 88,7 | −2,2 | L/M | 157,1 | 138,2 | −18,9 |
| CM/D | 10,4 | 17,3 | 6,9 | CM/D | 36,2 | 46,1 | 9,9 |
| G/B | 53,9 | 80,2 | 26,3 | G/B | 156,2 | 162,7 | 6,5 |
| A/P | 83,1 | 96,1 | 13 | A/P | 135,4 | 191,9 | 56,5 |
| V/V | 57 | 55,4 | −1,6 | V/V | 98,6 | 127,8 | 29,2 |
| T/F | 56,4 | 73,1 | 16,7 | T/F | 109,6 | 213,9 | 104,3 |
| L/L | 43,8 | 53,7 | 9,9 | L/L | 76,9 | 107,2 | 30,3 |
| G/M | 19,8 | 13,9 | −5,9 | G/M | 14,2 | 8,3 | −5,9 |
| G/C | 64,2 | 77,9 | 13,7 | G/C | 43,1 | 18,8 | −24,3 |
| G/V | 75,1 | 71,8 | −3,3 | G/V | 120,9 | 161,1 | 40,2 |
| N/C | 88,5 | 90 | 1,5 | N/C | 147,9 | 119,2 | −28,7 |
| C/A | 12,2 | 24,6 | 12,4 | C/A | 57,8 | 77,9 | 20,1 |
| A/A | 52,4 | 68,9 | 16,5 | A/A | 179,4 | 186,1 | 6,7 |
| N/S | 82,8 | 95,7 | 12,9 | N/S | 151,8 | 188,5 | 36,7 |
| M/D | 56 | 55,2 | −0,8 | M/D | 114,6 | 142,5 | 27,9 |
| F/F | 58,6 | 75,2 | 16,6 | F/F | 125,2 | 219,7 | 94,5 |
| S/E | 44,4 | 54,3 | 9,9 | S/E | 87,1 | 131,6 | 44,5 |
| D/B | 20,4 | 16,7 | −3,7 | D/B | 29 | 21,1 | −7,9 |
Electroretinogram (full-field) results
| Mean at 2 weeks after double filling removal (standard deviation) | 55.6 (24.7) |
| Mean at 8 weeks after double filling removal (standard deviation) | 61.6 (26.0) |
| 95% confidence interval for means difference of a correlated sample with paired data (tα/2 at 19 degrees of freedom is equal to 2.093) | 1.02;10.86 |
Note:
The interval excludes the 0 so that the difference of means is statistically significant.
Bright flash electroretinogram results
| Mean at 2 weeks after double filling removal (standard deviation) | 107.2 mV (49.7) |
| Mean at 8 weeks after double filling removal (standard deviation) | 128.9 mV (65.8) |
| 95% confidence interval for means difference of a correlated sample with paired data (tα/2 at 19 degrees of freedom is equal to 2.093) | 4.43;38.98 |
Note:
The interval excludes the 0 so that the difference of means is statistically significant.